Author

Lucie Aubergeon

Centre National de la Recherche ScientifiqueORCID 0000-0002-3459-7904Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Approach:benchmark study· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Agostina StradellaiD· 1 shared Ahmed IdbaïhiD· 1 shared Alexandrine GarnieriD· 1 shared Alice TalpiniD· 1 shared Amandine ManteauiD· 1 shared Ana Rita R. MaiaiD· 1 shared Camille GaaliD· 1 shared Carolina CalderoniD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Agostina StradellaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for Cancer

Alice Talpin, Ana Rita R. Maia, Jean-Marie Carpier, Guillaume Kulakowski, Lucie Aubergeon, Jérôme Kervevan, Camille Gaal, Francesco Strozzi, Coline Billerey, Ludivine Amable, Tifanny Mersceman, Alexandrine Garnier, Catia Pereira Oliveira, Carolina Calderon, Diana Bachrouche, , Joao Gamelas Magalhaes

This paper introduces OncoMimics, a peptide-based immunotherapy using molecular mimicry between commensal bacterial and tumor antigens to induce cross-reactive T cell responses, showing early clinical success in glioblastoma.

Journal for ImmunoTherapy of Cancer · Feb 1, 2025Peer-reviewedImmunology

Targeting B and T lymphocyte attenuator regulates lupus disease development in NZB/W mice

Léa Gherardi, Lucie Aubergeon, Mélanie Sayah, Jean‐Daniel Fauny, Hélène Dumortier, Fanny Monneaux

This study shows that targeting BTLA with a monoclonal antibody delays lupus onset and improves survival in NZB/W mice by reducing follicular B cells and exhibiting agonist activity.

ImmunoTargets and Therapy · Jan 1, 2025Peer-reviewedImmunology